AcuraStem is a patient-based biotechnology company pioneering treatments for neurodegenerative diseases including sporadic ALS and FTD. AcuraStem's best-in-class disease modeling platform, iNeuroRx®, enables the discovery of innovative, effective, and broadly acting treatments. The team's strong expertise in ASO technology provides for the rapid advancement of treatments to the clinic.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/30/24 | $7,000,000 | Grant |
Department of Defense National Institutes of Health | undisclosed |
